Literature DB >> 27778420

Urinary renalase concentration in patients with preserved kidney function undergoing coronary angiography.

Maciej T Wybraniec1, Maria Bożentowicz-Wikarek2, Jerzy Chudek2, Katarzyna Mizia-Stec1.   

Abstract

AIM: The purpose of the study was to evaluate urinary renalase concentration before and after coronary angiography/percutaneous coronary interventions (CA/PCI) in patients with coronary artery disease (CAD) and preserved kidney function and verify its potential application as contrast-induced acute kidney injury (CI-AKI) diagnostic marker.
METHODS: This prospective study comprised 95 consecutive patients (69.5% men; median age 65 years) with CAD submitted to elective or urgent CA/PCI. Data regarding 128 clinical variables were obtained. Urine samples were collected on admission and 6 h after CA/PCI and tested for urinary renalase using ELISA method, which was expressed as renalase-to-creatinine ratio. The CI-AKI diagnosis was based on ≥50% relative or ≥0.3 mg/dl absolute increase of serum creatinine concentration 48 h following the procedure.
RESULTS: Nine patients developed CI-AKI (9.5%). In comparison to baseline values, urinary renalase-to-creatinine ratio significantly decreased 6 h following CA/PCI, (2843.6 vs.1540.7 ng/mg, P < 0.0001). Nine patients developed CI-AKI (9.5%).The reduction of renalase level was profound both in CI-AKI (2709.7 vs. 1585.7 ng/mg, P = 0.007) and non-CI-AKI group (2814.9 vs.1561.8 ng/mg, P < 0.0001). There was a trend towards a greater relative decrease of urinary renalase in CI-AKI group (-57.3 vs.-41.8%, P = 0.10). Univariate analysis revealed that both pre- and post-procedural urinary renalase did not predict CI-AKI onset; however, absolute decrease of renalase below 25 percentile was a predictor of CI-AKI (OR = 5.4, 95% CI:1.3-21.9, P = 0.027).
CONCLUSION: Urinary renalase concentration is reduced in the aftermath of CA/PCI, which may be related to CI-AKI development. Further studies are warranted to elucidate the role of urinary renalase as a CI-AKI diagnostic marker.
© 2016 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  contrast-induced acute kidney injury; renalase; urinary markers

Mesh:

Substances:

Year:  2018        PMID: 27778420     DOI: 10.1111/nep.12954

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  5 in total

1.  The role of urinary renalase on early-stage renal damage in Chinese adults with primary hypertension.

Authors:  Na-Na You; Wei-Hong Jiang; Ming-Yuan Lin; Xiao-Gang Li; Yu-Yan Wu; Jia-Ying Li; Xiao-Yu Zhou; Ze-Wen Ding; Jun-Wen Wang; Xie-Xiong Zhao; Hui-Ling Chen; Hui-Ting Tang
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-26

2.  Relationship between Renalase Expression and Kidney Disease: an Observational Study in 72 Patients Undergoing Renal Biopsy.

Authors:  Yi-Sha Huang; Jian-Bo Lai; Sheng-Fa Li; Ting Wang; Ying-Nan Liu; Qing-Xia Zhang; Shu-Yuan Zhang; Chun-Han Sun; Nan Hu; Xin-Zhou Zhang
Journal:  Curr Med Sci       Date:  2018-04-30

3.  Serum Renalase Levels Are Predicted by Brain-Derived Neurotrophic Factor and Associated with Cardiovascular Events and Mortality after Percutaneous Coronary Intervention.

Authors:  I-Te Lee; Wayne Huey-Herng Sheu
Journal:  J Clin Med       Date:  2018-11-12       Impact factor: 4.241

4.  Association of renalase with clinical outcomes in hospitalized patients with COVID-19.

Authors:  Basmah Safdar; Melinda Wang; Xiaojia Guo; Charles Cha; Hyung J Chun; Yanhong Deng; James Dziura; Joe M El-Khoury; Fred Gorelick; Albert I Ko; Alfred I Lee; Robert Safirstein; Michael Simonov; Bin Zhou; Gary V Desir
Journal:  PLoS One       Date:  2022-03-08       Impact factor: 3.240

5.  Atorvastatin facilitates protection against contrast-induced nephropathy in patients undergoing coronary angiography via humoral mediators rather than altered renal hemodynamics.

Authors:  Maciej T Wybraniec; Artur Filipecki; Jerzy Chudek; Katarzyna Mizia-Stec
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-06-19       Impact factor: 1.426

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.